Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer
April 15, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Announces Issuance of U.S. Patent Covering Use of Proprietary Bifidobacterium animalis ssp. lactis Strain for Treating Cancer
March 05, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases
March 02, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences to Present at 40th Annual Cowen Health Care Conference
February 25, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
February 13, 2020 07:00 ET
|
Evelo Biosciences, Inc.
—Strong 2019 marked by clinical data that validates platform——Lead inflammation candidate EDP1815 showed positive clinical data across two separate cohorts——EDP1815 Phase 2 study initiation expected...
Evelo Biosciences to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020
February 06, 2020 08:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration
January 10, 2020 07:00 ET
|
Evelo Biosciences, Inc.
-- EDP1815 Phase 2 Interim Data in Psoriasis Expected by Year-End 2020 -- CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology...
Evelo Biosciences Appoints Juan Andres to Board of Directors
December 05, 2019 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference
November 13, 2019 08:01 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
November 08, 2019 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...